So this new peptide from the gut had potential to influence blood glucose in two ways, both by stimulating glucose-induced insulin release and by inhibiting glucagon secretion, both of which would limit hepatic glucose production, the main driver of the fasting hyperglycemia of type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.